BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, January 7, 2025
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» S-4321, a dual-cell bidirectional antibody that agonizes inhibitory receptors at the T cell-APC synapse
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immune
S-4321, a dual-cell bidirectional antibody that agonizes inhibitory receptors at the T cell-APC synapse
Dec. 4, 2024
No Comments
Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.
BioWorld Science
Conferences
American College of Rheumatology
Immune
Antibody
